Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioNotebook: Halozyme falters; Baxter acquires Chatham; Celgene buys Acceleron shares; and IPOs lose momentum

This article was originally published in Scrip

Executive Summary

Halozyme Therapeutics closed down 27.3% at $8.43 per share on 4 April after it revealed a temporary halt for an ongoing Phase II clinical trial testing the San Diego-based company's PEGPH20 in pancreatic cancer patients treated with nab-paclitaxel and gemcitabine.

Advertisement

Related Content

Competition Coming For Hemophilia Franchises, But Will Patients And Payers Embrace New Drugs?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC024966

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel